Combined use of DPP IV inhibitors and gastrin compounds

Details for Australian Patent Application No. 2006301892 (hide)

Owner Waratah Pharmaceuticals, Inc.

Inventors Cruz, Antonio

Agent Peter Maxwell & Associates

Pub. Number AU-A-2006301892

PCT Pub. Number WO2007/041833

Priority 60/724,919 07.10.05 US

Filing date 6 October 2006

Wipo publication date 19 April 2007

International Classifications

A61K 38/22 (2006.01) Medicinal preparations containing peptides - Hormones

A61K 31/4985 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

A61P 5/50 (2006.01) Drugs for disorders of the endocrine system

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/12 (2006.01) Drugs for disorders of the cardiovascular system

C07K 14/595 (2006.01) Peptides having more than 20 amino acids

C12N 9/48 (2006.01) Enzymes, e.g. ligases (6.) - acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)

Event Publications

8 May 2008 PCT application entered the National Phase

  PCT publication WO2007/041833 Priority application(s): WO2007/041833

3 May 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006301896-Cathepsin cysteine protease inhibitors

2006301891-Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment